Prof. Leo Heunks, MD, PhD, Amsterdam UMC, coordinating investigator for the study commented, “We’re very encouraged by these results, which indicate that the VentFree has the potential to meaningfully improve patient outcomes both during the COVID-19 pandemic and beyond.”
“We’re excited to announce these results” said Angus McLachlan, Liberate Medical Chief Executive Officer. “Reducing the time patients are on mechanical ventilation may reduce the risks of prolonged mechanical ventilation, which include muscle weakness, hospital-acquired infections, and deteriorated quality of life – a frequent outcome for so-called COVID-19 ‘long-haulers.’”
VentFree recently received FDA Emergency Use Authorization for use during the COVID-19 pandemic. Last year, VentFree received FDA Breakthrough Device Designation and CE marking in the European Union.